ranibizumab-nuna Byooviz
Selected indexed studies
- Ranibizumab. (, 2006) [PMID:29999635]
- Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial. (JAMA Ophthalmol, 2023) [PMID:36520462]
- Usability of the SB11 Pre-filled Syringe (PFS) in Patients with Retinal Diseases. (Adv Ther, 2024) [PMID:38976126]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ranibizumab. (2006) pubmed
- Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial. (2023) pubmed
- Usability of the SB11 Pre-filled Syringe (PFS) in Patients with Retinal Diseases. (2024) pubmed
- Physicochemical and Biological Stability Assessment of SB11 (Ranibizumab Biosimilar) Under Ambient and In-Use Storage for Intravitreal Administration. (2023) pubmed
- Switching to the Biosimilar Ranibizumab-nuna for the Intravitreal Treatment of Retinal Diseases - a Real-World Study. (2026) pubmed
- Drugs for age-related macular degeneration. (2025) pubmed
- A ranibizumab ocular implant (Susvimo) for age-related macular degeneration. (2022) pubmed
- Faricimab (Vabysmo) for age-related macular degeneration and diabetic macular edema. (2022) pubmed
- Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis(®) (Ranibizumab) Biosimilar. (2022) pubmed